Diagnosed in 2010 with a rare form of skin cancer called infundibulocystic-type basal cell carcinoma, Donna Schuck had a series of procedures that took a toll on her body. Then, NYU Langone Health’s Perlmutter Cancer Center informed her of a clinical trial testing an immunotherapy called Libtayo® (cemiplimab) to treat the disease. The trial, led by Janice Mehnert, MD, professor in the Department of Medicine and associate director for clinical research at Perlmutter Cancer Center (and also Ms. Schuck’s medical oncologist), changed her life, Ms. Schuck tells the Cancer Research Institute in a series of video interviews commemorating Cancer Immunotherapy Month.
Ms. Schuck emphasizes the importance of a care team in guiding people with cancer through diagnosis and treatment.
“My doctors are constantly looking out for me,” Ms. Schuck says. “They are amazingly intuitive about asking me questions. They fight for me every step of the way.”
Watch more on the Cancer Research Institute’s YouTube channel.